他莫昔芬治疗乳腺癌患者的子宫内膜癌肉瘤1例并文献复习  

A Case of Endometrial Carcinosarcoma in a Breast Cancer Patient Treated with Tamoxifen and Literature Review

作　　者：臧娜 韩静怡 袁芳[2] 

机构地区：[1]青岛大学青岛医学院,山东 青岛 [2]青岛大学附属医院妇科,山东 青岛

出　　处：《临床医学进展》2025年第2期1287-1292,共6页Advances in Clinical Medicine

摘　　要：目的:回顾性分析1例有多年他莫昔芬服用史乳腺癌患者的子宫内膜癌肉瘤典型病例,并结合文献复习他莫昔芬与子宫内膜癌的关系、子宫内膜癌肉瘤的治疗。方法:以病例报告的方式,结合文献复习,综合认识子宫内膜癌肉瘤的诊疗,分析他莫昔芬治疗史与子宫内膜癌的关系与管理,以降低乳腺癌他莫昔芬治疗患者的子宫内膜癌的发生率。结果:多年他莫昔芬服用史会明显增加子宫内膜癌的患病率,子宫癌肉瘤应注重个体化治疗。结论:应该注重他莫昔芬服用患者的妇科管理,同时子宫内膜癌肉瘤预后差,应重视对子宫内膜癌肉瘤患者的个体化治疗及分子检测的风险分层。Objective: Retrospective analysis of a typical case of endometrial carcinosarcoma in a breast cancer patient with a history of tamoxifen administration for many years. The study also reviewed the literature to explore the relationship between tamoxifen and endometrial cancer, as well as the treatment strategies for endometrial carcinosarcoma. Methods: Through a case report approach, combined with a review of the literature, this study provides a comprehensive understanding of the diagnosis and treatment of endometrial carcinosarcoma. It analyzes the relationship between tamoxifen treatment history and endometrial cancer, as well as its management, with the aim of reducing the incidence of endometrial cancer in breast cancer patients undergoing tamoxifen therapy. Results: A history of tamoxifen administration for many years significantly increases the prevalence of endometrial cancer, and endometrial carcinosarcoma should be focused on individualized treatment. Conclusion: Gynecologic management of tamoxifen-taking patients should be emphasized, as well as the poor prognosis of endometrial carcinosarcoma, and individualized treatment and risk stratification by molecular testing should be emphasized for patients with endometrial.

关 键 词：他莫昔芬 子宫内膜癌肉瘤 乳腺癌 

分 类 号：R73[医药卫生—肿瘤]